PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.52%
Positive EBIT growth while Biotechnology median is negative. Peter Lynch might see a strong competitive advantage in operations.
16.52%
Positive operating income growth while Biotechnology is negative. Peter Lynch would spot a big relative advantage here.
16.61%
Positive net income growth while Biotechnology median is negative. Peter Lynch would view this as a notable competitive advantage.
17.14%
EPS growth of 17.14% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
17.14%
Diluted EPS growth of 17.14% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend cuts while Biotechnology median is 0.00%. Seth Klarman would see if others maintain or grow payouts, highlighting a relative weakness.
9.84%
Positive OCF growth while Biotechnology median is negative. Peter Lynch might see a strong relative advantage in operational efficiency.
13.18%
Positive FCF growth while Biotechnology median is negative. Peter Lynch might view this as a notable advantage over peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2671.03%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
90.48%
OCF/share CAGR of 90.48% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
83.42%
3Y OCF/share growth of 83.42% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-2587.91%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
90.30%
Net income/share CAGR of 90.30% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
86.48%
3Y net income/share CAGR of 86.48% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
1551.35%
Equity/share CAGR of 1551.35% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
-71.69%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-47.82%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Asset growth of 13.10% while Biotechnology median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
15.36%
BV/share growth of 15.36% while Biotechnology is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-14.09%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
-7.82%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-4.34%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.